Full-Time

Manager – Computational Biology

Early Oncology

Recursion

Recursion

501-1,000 employees

Data-driven drug discovery platform leveraging datasets

Compensation Overview

$151.8k - $220.6k/yr

+ Annual Bonus + Equity Compensation

Salt Lake City, UT, USA + 1 more

More locations: New York, NY, USA

Hybrid

Office-based, hybrid position; must work in the office at least 50% of the time.

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Python
R

Get referred to Recursion

See people who can refer or advise you

Requirements
  • PhD in a quantitative field (Computational Biology, Bioinformatics, Statistics, Cancer Biology, etc.) with 5+ years of experience in biotech or pharma industry
  • MS in a relevant field and 7+ years of experience in biotech or pharma industry solving fundamental problems in oncology or drug discovery
  • People Management Experience: Proven track record of managing and developing direct reports within a scientific or technical environment
  • Oncology Domain Expertise: Deep understanding of cancer biology, including experience with biomarker discovery and patient population stratification. Experience with two or more oncology areas; strong understanding of patient genetics and historical druggability of disease relevant pathways
  • Deep expertise in the analysis and data integration of two or more ‘omics data modalities (phenomics, transcriptomics, proteomics, genomics), including experience working with patient data
  • Exceptional data visualization skills
  • Computational Proficiency: Advanced skills in Python or R for the analysis of high-dimensional biological data (e.g., transcriptomics, proteomics, or high-content imaging)
  • Excellent Cross-Functional Communication: Ability to distill complex technical concepts into clear and compelling narrative for internal and external-cross functional audiences
Responsibilities
  • Lead and mentor a team of data scientists and computational biologists, fostering a culture of scientific rigor, bold experimentation, and continuous professional growth
  • Drive the design and execution of analyses for target nomination and validation, using Recursion’s platform to identify novel vulnerabilities in cancer biology
  • Define biomarker strategies and patient-stratification hypotheses to support programs as they progress from nomination through hit-to-lead and lead-optimization
  • Act as a key 'connector,' leading the team to pilot innovative analysis methods and collaborating with platform and engineering teams to productionalize and scale these tools for organization-wide impact
  • Maintain a 50% individual contribution load, performing complex data integration and analysis to solve 'killer questions' within the oncology portfolio
  • Partner with biologists, medicinal chemists, and clinical leads to build compelling data packages that drive program milestones and investment decisions
  • Present data analysis to external decision makers and stakeholders in a clear and compelling way that drives toward getting medicines to patients
Desired Qualifications
  • Public Data Mastery: Familiarity with large-scale oncology datasets such as TCGA, CCLE, DepMap, and/or Real-World Data (RWD)
  • Experimental Design: Experience designing high-throughput screens or CRISPR/small-molecule perturbations to validate therapeutic hypotheses
  • Clinical Translation: Exposure to the requirements for IND-enabling studies or clinical trial biomarker analysis

Recursion uses hardware, software, and data to accelerate drug discovery in the TechBio space, running thousands of wet-lab experiments weekly to profile genes and compounds across many cell types. It combines a massive proprietary dataset (about 50 petabytes) with a powerful computing platform, BioHive 1, to map billions of gene–compound relationships and generate actionable drug candidates. Its approach blends high-throughput experimentation with large-scale data science to create learning loops and partnerships with pharmaceutical companies, research institutions, and healthcare providers. Its goal is to decode biology at scale and discover and commercialize medicines that can improve patient lives.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Salt Lake City, Utah

Founded

2013

Get referred to Recursion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 cash operating expense guidance fell to $375 million, extending runway.
  • REC-4881 Phase 2 data arrives in November 2026, with FDA path updates.
  • Recursion has collected $216 million from Roche and Genentech since 2021.

What critics are saying

  • Revenue fell 60% year over year to $7.67 million in Q2 2026.
  • Roche collaboration phases ended, exposing Recursion's dependence on partnership milestones.
  • If REC-4881 or REC-7735 fail, Recursion becomes a cash-burning data factory.

What makes Recursion unique

  • Genentech advanced Recursion's first neuroscience target into early discovery on August 5, 2026.
  • REC-4881 targets FAP with dual MEK1/2 biology and FDA Fast Track designation.
  • REC-7735 earned IND clearance in August 2026, showing repeatable AI-designed chemistry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Hybrid Work Options

Company News

Yahoo Finance
Aug 6th, 2026
Recursion Pharmaceuticals shares fall 4.2% as Q2 revenue drops 60% to $7.67M

Recursion Pharmaceuticals reported a second-quarter loss of 25 cents per share, worse than the estimated 23-cent loss. This compares to a 41-cent loss in the year-ago quarter. Total revenues fell 60% year-over-year to $7.67 million, missing the $14 million estimate. The decline stemmed from lower collaboration revenues with Roche and Genentech following completion of certain project phases. Research and development expenses decreased 30% to $89.6 million, reflecting lower platform costs and improved efficiency. General and administrative expenses fell 11% to $41.5 million. The company held $556.8 million in cash as of 30 June, down from $665.2 million at quarter-end March. Recursion expects current cash reserves to fund operations into early 2028. Shares dropped 4.2% on Wednesday following the results.

Yahoo Finance
Aug 5th, 2026
Recursion cuts 2026 cash guidance to $375M, targeting FAP data in November

Recursion Pharmaceuticals reported Q2 2026 results, highlighting its AI-driven drug discovery platform's progress. The company lowered full-year 2026 cash operating expense guidance to $375 million, nearly 40% below 2024 levels. Recursion's collaboration with Roche-Genentech identified a previously unexplored neuroscience target, triggering part of $260 million in milestone payments. The platform can move from target to candidate in 1.5 years using approximately 330 compounds, versus industry benchmarks of 4 years and 2,500 compounds. The company holds approximately $557 million in cash, providing runway through early 2028. Phase II data for REC-4881 in FAP will be presented in November, with Phase I trial for REC-7735 expected later this year. Recursion appointed a new Chief AI Officer and Head of Drug Design to strengthen its AI capabilities.

Yahoo Finance
Aug 5th, 2026
Recursion Pharmaceuticals revenue drops to $7.67M but loss narrows as Genentech advances neuroscience programme

Recursion Pharmaceuticals reported mixed Q2 2026 results, with revenue falling to $7.67 million from $19.22 million year-over-year, though its net loss narrowed to $131.01 million. Loss per share improved to $0.25. The AI-driven drug discovery company announced that Genentech has advanced a neuroscience target into joint early discovery. Recursion also provided updates on REC-4881 Phase 2 data and the upcoming REC-7735 clinical trial. The company's cash runway extends through Q4 2027. Analysts had previously modelled revenue declining approximately 29.5% annually. Despite the revenue drop, shares rose 11.4% following the results and partnership milestone announcement. The stock's advance suggests investors focused on the Genentech collaboration progress rather than the quarterly revenue decline.

San Francisco Biotechnology Network
Aug 5th, 2026
Recursion partners with Genentech to advance first validated neuro target discovered through AI map.

Recursion partners with Genentech to advance first validated neuro target discovered through AI map. August 5, 2026 san francisco biotechnology network news news, syndication comments off on Recursion partners with Genentech to advance first validated neuro target discovered through AI map. The 4.5 year, up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion and Genentech to co-develop a neuroscience small molecule early discovery program based on the first validated target discovered through an AI map they created to find new targets in a long-challenging therapeutic area. Genentech has exercised the collaboration's first validated target option after accepting from Recursion a validation package for the target. That acceptance will trigger a $3 million milestone payment from the biopharma giants to Recursion. That latest payment raises to $216 million the total cash paid out by the biopharma giants to Recursion since the AI-based drug developer joined with the pharma giant and its subsidiary to launch their partnership in 2021. For each program developed, Recursion can receive up to $300 million in payments tied to achieving development, commercialization,... Click here to view original post

Associated Press
Aug 5th, 2026
Genentech opts first neuroscience target from Recursion's AI platform into discovery program

Recursion reported Q2 2026 financial results, highlighting progress in its drug discovery platform and pipeline advancement. The company's collaboration with Genentech achieved a key milestone, with the first neuroscience target advancing into an early discovery programme. Revenue for Q2 2026 was $7.7 million, down from $19.2 million in Q2 2025. Net loss decreased to $131 million from $171.9 million year-over-year. Cash position stood at $556.8 million as of 30 June 2026. Recursion reduced its 2026 cash operating expense guidance to under $375 million from under $390 million. The company expects its cash runway to extend into early 2028 based on current operating plans. The firm's REC-7735 PI3Kα inhibitor received IND clearance, with Phase 1/2 trials planned for the second half of 2026. Additional Phase 2 data for REC-4881 will be presented in November 2026.